Ipsen : 2023 CSM – Formalities for making available preparatory documents to the Meeting
Ipsen : 2023 CSM – Formalities for making available preparatory documents to the Meeting
INFORMATION RELATING TO THE HOLDING OF THE
COMBINED SHAREHOLDERS’ MEETING OF 31 MAY 2023
Ipsen : 2023 CSM – Formalities for making available preparatory documents to the Meeting
INFORMATION RELATING TO THE HOLDING OF THE
COMBINED SHAREHOLDERS’ MEETING OF 31 MAY 2023
Related Press Releases
Ipsen and Foreseen Biotechnology announce exclusive global licensing agreement for antibody-drug conjugate with first-in-class potential
IPSEN – Buy-back programme – Art 5 of MAR – Week 27 – 2024
Ipsen – June 2024 – Monthly information relative to the total number of voting rights and shares composing the share capital
Half-year statement of IPSEN liquidity agreement – 2024 06 30
IPSEN – Buy-back programme – Art 5 of MAR – Week 26 – 2024
Ipsen expands collaboration and license agreement for development of Cabometyx® in advanced neuroendocrine tumors based on positive CABINET Phase III trial
IPSEN – Buy-back programme – Art 5 of MAR – Week 25 – 2024
IPSEN – Buy-back programme – Art 5 of MAR – Week 24 – 2024
IPSEN – Buy-back programme – Art 5 of MAR – Week 23 – 2024
Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis